Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Cervical cancer is a type of cancer that occurs in the cells of the cervix — the lower part of the uterus that connects to the vagina. Pap smear, colposcopy, and ECC procedure are some of the tests used in diagnosis of cervical cancer.
The global cervical cancer diagnostic tests market is estimated to account for US$ 93.6 Mn in terms of value by the end of 2027.
Global Cervical Cancer Diagnostic Tests Market: Drivers
Increasing prevalence of cervical cancer is expected to propel growth of the global cervical cancer diagnostic tests market over the forecast period. For instance, according to the American Cancer Society, about 13,800 new cases of invasive cervical cancer are expected to be diagnosed in the U.S. in 2020 and the disease is expected to lead to death of 4,290 women in the same year.
Moreover, high number of smoking women is also expected to aid in growth of the market. Tobacco by-products have been found in the cervical mucus of women who smoke. According to Truth Initiative, the U.S.-based nonprofit public health organization, (March 2019), among high school students in the U.S., 7.3 percent of females and 8.8 percent of males currently smoke cigarettes.
North America held dominant position in the global cervical cancer diagnostic tests market in 2019, accounting for 37.0% share in terms of value, followed by Europe and Asia Pacific, respectively.
Figure 1: Global Cervical Cancer Diagnostic Tests Market Share (%) Value, By Region, 2019
Global Cervical Cancer Diagnostic Tests Market: Restraints
Stringent regulations and guidelines are expected to hinder growth of the market. Government recommendations and regulations suggest the initial age limit to be 21 for a pap test. American College of Obstetricians and Gynecologists suggests that the initial age limit for a pap smear test should be 21 or within the first three years of the first sexual intercourse, to avoid unnecessary treatment expenses.
Moreover, lack of appropriate healthcare infrastructure in underdeveloped and developing countries is also expected to limit the market growth.
Cervical Cancer Diagnostic Tests Market Report Coverage
||Market Size in 2019:
||US$ 77.1 Mn
|Historical Data for:
||2016 to 2019
||2020 to 2027
|Forecast Period 2020 to 2027 CAGR:
||2027 Value Projection:
||US$ 93.6 Mn
- North America: U.S., Canada
- Latin America: Brazil, Argentina, Mexico, Rest of Latin America
- Europe: Germany, U.K., France, Spain, Italy, Russia, Rest of Europe
- Asia Pacific: China, Japan, India, Australia, South Korea, ASEAN, Rest of Asia Pacific
- Middle East: GCC Countries, Israel, Rest of Middle East
- Africa: North Africa, Central Africa, South Africa
- By Test Type: Pap Smear Test Procedure, Colposcopy Procedure, ECC Procedures.
- By Age Group: Age 20 - 40, Age above 40.
Guided Therapeutics, Abbott Laboratories, Beckman Coulter Inc., and Becton, Dickinson and Company.
- Increasing prevalence of cervical cancer
- Approval and launch of new products
|Restraints & Challenges:
- Stringent regulatory guidelines
Global Cervical Cancer Diagnostic Tests Market: Opportunities
Increasing female geriatric population is expected to offer lucrative growth opportunities for players in the global cervical cancer diagnostic tests market. For instance, according to the U.S. Census Bureau, women aged 85 and older are projected to make up 2.9 percent of the total U.S. population in 2060.
Moreover, increasing prevalence of obesity is also expected to aid in growth of the market. For instance, according to the Centers of Disease Control and Prevention, Behavioral Risk Factor Surveillance System, 2018, 71424.3 thousand people in the U.S. suffer from obesity.
The global cervical cancer diagnostic tests market was valued at US$ 77.1 Mn in 2019 and is forecast to reach a value of US$ 93.6 Mn by 2027 at a CAGR of 2.4% between 2020 and 2027.
Figure 2: Global Cervical Cancer Diagnostic Tests Market Value (US$ Mn), 2016 – 2027
Market Trends/Key Takeaways
Major healthcare bodies are focused on promoting at-home screening for HPV and cervical cancer. For instance, in the U.S., The National Cancer Institute plans to launch a multisite study in 2021 involving roughly 5,000 women to assess whether self-sampling at home is comparable to screening in the office by a clinician.
Use of artificial intelligence (AI) is expected to enhance the efficacy of cervical cancer diagnostics. For instance, according to a study published in June 2020, in the Journal of the National Cancer Institute, a computer algorithm improved the accuracy and efficiency of cervical cancer screening compared with cytology (Pap test), the current standard for follow-up of women who test positive with primary human papillomavirus (HPV) screening.
Global Cervical Cancer Diagnostic Tests Market: Competitive Landscape
Major players operating in the global cervical cancer diagnostic tests market include, Guided Therapeutics, Abbott Laboratories, Beckman Coulter Inc., and Becton, Dickinson and Company.
Global Cervical Cancer Diagnostic Tests Market: Key Developments
Major players in the market are focused on approval and launch of new products to expand their product portfolio. For instance, in July 2020, Guided Therapeutics, Inc. received a new CE Mark, through its European contract manufacturer, Newmars Technologies, Kft., for its LuViva Advanced Cervical Scan.
Similarly, in March 2019, Abbott Laboratories received CE Mark for its Alinity m diagnostics system and assays.